DUBLIN, Ireland and PRAGUE, Czech Republic, October 11 /PRNewswire-FirstCall/ -- Alltracel Pharmaceuticals Plc., ("Alltracel", or "the Company"), (AIM:AP.L), the Medical Technology Company focussed on the Woundcare, Oralcare and Cardiovascular Health markets today announces the launch of NANOPEUTICS s.r.o. the specialist joint venture with Nanofibre technology innovators Elmarco. NANOPEUTICS is dedicated to the commercialisation of Nanospider(TM) technology for the global professional and consumer woundcare markets and will be led by Ladislav Mares, current CEO of Elmarco, as chairman and by Camillus Glover, currently COO of Alltracel, as CEO.
Elmarco is a specialist R&D and manufacturing company that has developed, in conjunction with the Technical University of Liberic, a novel proprietary & patented process for spinning polymers into nano-scale fibres for a range of industrial, chemical, micro-electronic and bio-medical applications. This proprietary technology branded Nanospider", represents a major breakthrough in the mass production of nanofibre materials and is now deployed in a number of markets including medical products.
NANOPEUTICS headquartered in Liberic in the Czech Republic and operating internationally has been assigned the relevant woundcare and Nanospider(TM) intellectual property and patents and has already been in advanced discussions including successful product testing with a number of existing consumer and professional woundcare companies.
Chairman of NANOPEUTICS, and CEO of Elmarco Ladislav Mares, commented:
"We are confident that NANOPEUTICS is the correct route-to-market for our Nanospider(TM) technology for the global woundcare market. Medical devices applications has always been one of our key development target markets and the last few months have demonstrated that woundcare is one of the most advanced markets in terms of bringing commercially viable innovative nanofibre based products to market. Following several woundcare product test programs we have seen significant improvements in advanced active materials efficacy and manufacturing efficiency and versatility, facilitated by the Nanospider(TM) technology".
Alltracel's CEO, Tony Richardson, commented:
"The formation of NANOPEUTICS represents a significant move for Alltracel into the advanced woundcare market in both the consumer and professional sectors. Since announcing the formation of the JV this summer we have been working with Elmarco and a number of potential woundcare partners in successfully testing a number of advanced woundcare product concepts.
We are excited about the significant commercial prospects for not only our own m.doc(TM) stops bleeding technology platform, but also for the incorporation of other active materials into a conventional wound-pad.
"Commercialising this breakthrough technology in the global woundcare market via NANOPEUTICS is now a priority business development focus for Alltracel and represents our bridgehead into the EUR10 billion professional woundcare sector."
For Further Information Contact: Dublin: Denise Cronin, Alltracel: +353-1-235-2162, press@alltracel.com London: Deborah Scott, Financial Dynamics: +44-(0)207-831-3113 New York: Sean Leous, Financial Dynamics: +1-212-850-5626 Notes to Editors:
Elmarco (www.elmarco.cz) is a specialist R&D and manufacturing company that has developed, in conjunction with the Technical University of Liberic, a novel proprietary & patented process for spinning polymers into nano-scale fibres for a range of industrial, chemical, micro-electronic and bio-medical applications. This proprietary technology branded Nanospider", represents a major breakthrough in the mass production of nanofibre materials and is now deployed in a number of markets including medical products.
Alltracel (AIM: AP.L) (www.alltracel.com) Alltracel Pharmaceuticals Plc is a Medical Technology Company focussed on the Woundcare, Oralcare and Cardiovascular Health markets.
With corporate headquarters in Dublin, Ireland; Alltracel has a commercial office in London, England; R&D subsidiary in the Czech Republic and manufacturing facilities in Shenzhen, China. Alltracel was founded in 1996 and listed on London's Alternative Investment Market in July 2001.
Alltracel's has a number of patents in the areas of polysaccharide manipulation and PTFE processes and products as well as a significant collaborative R&D programme in place focussed on its markets.
In the Woundcare market m-doc(TM) (Micro Dispersed Oxidized Cellulose; (www.m-doc.com)) is the trading name given to Alltracel's patented technology which is proven as an effective and efficient haemostatic (blood-stopping) agent.
- In the consumer Woundcare sector m-doc(TM) is currently being marketed as the leading stops bleeding ingredient brand within recognized woundcare, and relevant first-aid brands worldwide.
- Alltracel's woundcare technology is also currently poised for entry into the professional Woundcare and specialist Oralcare markets.
Within the Cardiovascular Health market Alltracel (www.alltracelcvh.com) has developed a novel bioactive compound that, following two years of scientific research including in vitro, pre-clinical and clinical trials indicates cardiovascular health (CVH) benefits on its own and in combination with existing CVH products.
Alltracel's patented process utilises a derivative of cellulose fibre to produce a bioactive with scientifically proven properties that aid CVH; specifically lowering LDL cholesterol, reducing blood glucose levels and helping to prevent arterial plaque build up.
The end result is a pioneering, value-adding bioactive that can enhance and differentiate current cardiovascular health products and that can add benefit to current non-health benefiting nutritious finished foods.
- Further efficacy, dosage, timing/phasing and combination (with other bio-actives) studies to determine optimum delivery systems, formats and combinations in both the functional foods and pharmaceutical markets are underway.
- Development discussions with potential partners in the functional foods and pharmaceutical sectors in the EU, Asia and North America have commenced.
m-doc(TM) is a trademark of Alltracel Pharmaceuticals PLC.
Alltracel Pharmaceuticals Plc.CONTACT: For Further Information Contact: Dublin: Denise Cronin,Alltracel: +353-1-235-2162, press@alltracel.com. London: Deborah Scott,Financial Dynamics: +44-(0)207-831-3113. New York: Sean Leous, FinancialDynamics: +1-212-850-5626
